Ezetimibe/rosuvastatin - Navipharm

Drug Profile

Ezetimibe/rosuvastatin - Navipharm

Alternative Names: NVP-1205; Rosuvastatin/ezetimibe - Navipharm

Latest Information Update: 03 Aug 2016

Price : $50

At a glance

  • Originator Navipharm
  • Class Antihyperlipidaemics; Azetidines; Fluorobenzenes; Propanols; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action Cholesterol absorption inhibitors; HMG-CoA reductase inhibitors; NPC1L1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Dyslipidaemias

Most Recent Events

  • 12 Nov 2014 Navipharm Corporation plans a phase I trial in Healthy male volunteers in South Korea (NCT02289430)
  • 22 Jan 2014 Preclinical trials in Dyslipidaemias in South Korea (unspecified route)
  • 22 Jan 2014 Navipharm Corporation plans a phase I pharmacokinetic trial in Healthy volunteers in South Korea (NCT02029625)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top